USEUROPEAFRICAASIA 中文双语Français
Home / Business

Chinese drugmaker BeiGene shares soar on US market

By Wu Yiyao in Shanghai | China Daily | Updated: 2018-01-05 07:29

The share price of Nasdaq-listed Chinese biopharmaceutical company BeiGene more than tripled in 2017 even though its products have not yet been put on the market, indicating investors' strong interest in the company's offerings.

Even though it's rare for a company's share price to skyrocket when its products are yet to be offered, a report from the Motley Fool, a US investment analytics website, indicates there is still more potential for the stock to grow, supported by BeiGene's fundamentals.

BeiGene is a commercial-stage, research-based biopharmaceutical company focused on molecularly targeted and immune-oncology cancer therapeutics. Its share price rose from some $30 to more than $96 in 2017, with capitalization of about $4.4 billion.

Chinese drugmaker BeiGene shares soar on US market

Today's Top News

Editor's picks

Most Viewed

Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US